Search

Your search keyword '"Sokol, Lubomir"' showing total 535 results
Start Over Author "Sokol, Lubomir" Publication Type Academic Journals
535 results on '"Sokol, Lubomir"'

1. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

Author

Witzig, Thomas, Sokol, Lubomir, Kim, Won Seog, de la Cruz Vicente, Fátima, Martín García-Sancho, Alejandro, Advani, Ranjana, Roncero Vidal, Jose Maria, de Oña Navarrete, Raquel, Marín-Niebla, Ana, Rodriguez Izquierdo, Antonia, Terol, María José, Domingo-Domenech, Eva, Saunders, Andrew, Bendris, Nawal, Mackey, Julie, Leoni, Mollie, and Foss, Francine

Published
2024
Full Text
View/download PDF

2. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Author

Bhansali, Rahul S., Ellin, Fredrik, Relander, Thomas, Cao, Miao, Li, Wenrui, Long, Qi, Ganesan, Nivetha, Stuver, Robert, Horwitz, Steven M., Wudhikarn, Kitsada, Hwang, Steven R., Bennani, N. Nora, Chavez, Julio, Sokol, Lubomir, Saeed, Hayder, Duan, Frank, Porcu, Pierluigi, Pullarkat, Priyanka, Mehta-Shah, Neha, Zain, Jasmine M., Ruiz, Miguel, Brammer, Jonathan E., Prakash, Rishab, Iyer, Swaminathan P., Olszewski, Adam J., Major, Ajay, Riedell, Peter A., Smith, Sonali M., Goldin, Caroline, Haverkos, Bradley, Hu, Bei, Zhuang, Tony Z., Allen, Pamela B., Toama, Wael, Janakiram, Murali, Brooks, Taylor R., Jagadeesh, Deepa, Hariharan, Nisha, Goodman, Aaron M., Hartman, Gabrielle, Ghione, Paola, Fayyaz, Fatima, Rhodes, Joanna M., Chong, Elise A., Gerson, James N., Landsburg, Daniel J., Nasta, Sunita D., Schuster, Stephen J., Svoboda, Jakub, Jerkeman, Mats, and Barta, Stefan K.

Published
2024
Full Text
View/download PDF

3. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis

Author

Chavez, Julio C, Grajales, Ariel, Sandoval-Sus, Jose, Turba, Elyce, Nodzon, Lisa, Uriepero-Palma, Angimar, Ammad-Ud-Din, Mohammad, Sahakian, Eva, Komrokji, Rami, Sokol, Lubomir, Locke, Frederick L, Shah, Bijal, Lancet, Jeffrey, Sotomayor, Eduardo M, Kharfan-Dabaja, Mohamed A., Bello, Celeste, and Pinilla-Ibarz, Javier

Published
2024
Full Text
View/download PDF

5. Sézary syndrome originates from heavily mutated hematopoietic progenitors

Author

Harro, Carly M., Sprenger, Kimberly B., Chaurio, Ricardo A., Powers, John J., Innamarato, Patrick, Anadon, Carmen M., Zhang, Yumeng, Biswas, Subir, Mandal, Gunjan, Mine, Jessica A., Cortina, Carla, Nagy, Mate Z., Martin, Alexandra L., Handley, Katelyn F., Borjas, Gustavo J., Chen, Pei-Ling, Pinilla-Ibarz, Javier, Sokol, Lubomir, Yu, Xiaoqing, and Conejo-Garcia, Jose R.

Published
2023
Full Text
View/download PDF

7. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Author

Ruan, Jia, Moskowitz, Alison, Mehta-Shah, Neha, Sokol, Lubomir, Chen, Zhengming, Kotlov, Nikita, Nos, Grigorii, Sorokina, Maria, Maksimov, Vladislav, Sboner, Andrea, Sigouros, Michael, van Besien, Koen, Horwitz, Steven, Rutherford, Sarah C., Mulvey, Erin, Revuelta, Maria V., Xiang, Jenny, Alonso, Alicia, Melnick, Ari, Elemento, Olivier, Inghirami, Giorgio, Leonard, John P., Cerchietti, Leandro, and Martin, Peter

Published
2023
Full Text
View/download PDF

9. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Author

Barilà, Gregorio, Grassi, Angela, Cheon, HeeJin, Teramo, Antonella, Calabretto, Giulia, Chahal, Jasmanet, Vicenzetto, Cristina, Almeida, Julia, Shemo, Bryna C., Shi, Min, Gasparini, Vanessa Rebecca, Munoz-Garcia, Noemi, Pastoret, Cédric, Nakazawa, Hideyuki, Oshimi, Kazuo, Sokol, Lubomir, Ishida, Fumihiro, Lamy, Thierry, Orfao, Alberto, Morice, William G., Loughran, Thomas P., Jr., Semenzato, Gianpietro, and Zambello, Renato

Published
2023
Full Text
View/download PDF

10. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion

Author

Zhang, Yumeng, Nguyen, Lynn, Lu, Chuanyi M., Wang, Endi, Lauw, Marietya I.S., Ball, Somedeb, Dong, Ning, Moscinski, Lynn, Chan, Onyee, Yun, Seongseok, Sallman, David, Sokol, Lubomir, Shah, Bijal, Knepper, Todd, Lancet, Jeffery, Komrokji, Rami, Padron, Eric, Kuykendall, Andrew, and Zhang, Ling

Published
2023
Full Text
View/download PDF

11. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Author

Zhang, Yumeng, Rose, Ashley, Khadka, Sushmita, Cao, Biwei, Eatrides, Jennifer, Saeed, Hayder, Shah, Bijal D., Chavez, Julio, Bello, Celeste, Lazaryan, Aleksandr, Khimani, Farhad, Ibarz, Javier Pinilla, Liu, Hien D., Locke, Frederick L., Jain, Michael D., Zhang, Ling, Kharfan-Dabaja, Mohamed A., Kim, Jongphil, Ayala, Ernesto, Nishihori, Taiga, and Sokol, Lubomir

Published
2024
Full Text
View/download PDF

12. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.

Author

LOGOTHETIS, CONSTANTINE N., HORVAT, NATHAN P., KURIAN, TONY, BELLO, CELESTE, ISENALUMHE, JULIO LEIDY, SHAH, BIJAL, SOKOL, LUBOMIR, SAEED, HAYDER, PINILLA, JAVIER, and GABALLA, SAMEH

Subjects
MUCOSA-associated lymphoid tissue lymphoma, PROGRESSION-free survival, RITUXIMAB, DIFFUSE large B-cell lymphomas, OVERALL survival, SURVIVAL rate
Abstract

Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40--81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0--6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was 100.0% (60.0% complete response, 40.0% partial response). Medians of overall survival and progression-free survival were not reached. The estimated 2-year progression-free survival was 85.2% and overall survival was 100.0%. Four (16.6%) patients had infections related to treatment; 3 (12.0%) transformed to diffuse large B-cell lymphoma; 5 (20.8%) had a relapse or progression of EMZL; and 3 (12.0%) died unrelated to BR. BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Orphan Drug, Hematology, Clinical Research, Rare Diseases, Lymphoma, Cancer, Algorithms, Comorbidity, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Staging, Prognosis, National comprehension cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Published
2015

16. Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis

Author

McGraw, Kathy L., Cheng, Chia-Ho, Chen, Y. Ann, Hou, Hsin-An, Nilsson, Björn, Genovese, Giulio, Cluzeau, Thomas, Pellagatti, Andrea, Przychodzen, Bartlomiej P., Mallo, Mar, Arenillas, Leonor, Mohamedali, Azim, Adès, Lionel, Sallman, David A., Padron, Eric, Sokol, Lubomir, Moreilhon, Chimene, Raynaud, Sophie, Tien, Hwei-Fang, Boultwood, Jacqueline, Ebert, Benjamin L., Sole, Francesc, Fenaux, Pierre, Mufti, Ghulam J., Maciejewski, Jaroslaw P., Kanetsky, Peter A., and List, Alan F.

Published
2019
Full Text
View/download PDF

17. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Author

O'Connor, Owen A., Falchi, Lorenzo, Lue, Jennifer K., Marchi, Enrica, Kinahan, Cristina, Sawas, Ahmed, Deng, Changchun, Montanari, Francesca, Amengual, Jennifer E., Kim, Hye A., Rada, Aishling M., Khan, Karen, Jacob, Alice T., Malanga, Michelle, Francescone, Mark M., Nandakumar, Renu, Soderquist, Craig R., Park, David C., Bhagat, Govind, Cheng, Bin, Risueño, Alberto, Menezes, Daniel, Shustov, Andrei R., Sokol, Lubomir, and Scotto, Luigi

Published
2019
Full Text
View/download PDF

20. Non-Hodgkin's lymphomas, version 4.2014.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Stem Cell Research, Lymphoma, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Recurrence, National comprehensive cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Published
2014

21. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Author

Verstovsek, Srdan, Tam, Constantine S, Wadleigh, Martha, Sokol, Lubomir, Smith, Catherine C, Bui, Lynne A, Song, Chunyan, Clary, Douglas O, Olszynski, Patrycja, Cortes, Jorge, Kantarjian, Hagop, and Shah, Neil P

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hematology, Rare Diseases, Clinical Research, Peripheral Neuropathy, Neurodegenerative, Neurosciences, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Drug Monitoring, Early Termination of Clinical Trials, Female, Humans, Janus Kinase 2, Male, Middle Aged, Neurotoxicity Syndromes, Primary Myelofibrosis, Proline, Protein Kinase Inhibitors, Pyrimidines, Myelofibrosis, JAK2, XL019, Mutation, Inhibitor, Immunology, Cardiovascular medicine and haematology
Abstract

This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300 mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21 h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.

Published
2014

23. MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3

Author

Zhang, Yumeng, Lu, Chuanyi, Wang, Endi, Nguyen, Lynh, Lauw, Marietya, Ball, Somedeb, Dong, Ning, Moscinski, Lynn, Chan, Onyee, Yun, Seongseok, Sallman, David, Sokol, Lubomir, Shah, Bijal, Knepper, Todd, Lancet, Jeffrey, Komrokji, Rami, Kuykendall, Andrew, Padron, Eric, and Zhang, Ling

Published
2022
Full Text
View/download PDF

25. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study

Author

Basiorka, Ashley A, McGraw, Kathy L, Abbas-Aghababazadeh, Farnoosh, McLemore, Amy F, Vincelette, Nicole D, Ward, Grace A, Eksioglu, Erika A, Sallman, David A, Ali, Najla Al, Padron, Eric, Pinilla-Ibarz, Javier, Komrokji, Rami, Masala, Erico, Santini, Valeria, Kosmider, Olivier, Fontenay, Michaela, Fenaux, Pierre, Sokol, Lubomir, Wei, Sheng, Fridley, Brooke, and List, Alan F

Published
2018
Full Text
View/download PDF

26. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

Author

Yazbeck, Victor, Shafer, Danielle, Perkins, Edward B., Coppola, Domenico, Sokol, Lubomir, Richards, Kristy L., Shea, Thomas, Ruan, Jia, Parekh, Samir, Strair, Roger, Flowers, Christopher, Morgan, David, Kmieciak, Maciej, Bose, Prithviraj, Kimball, Amy, Badros, Ashraf Z., Baz, Rachid, Lin, Hui-Yi, Zhao, Xiuhua, Reich, Richard R., Tombes, Mary Beth, Shrader, Ellen, Sankala, Heidi, Roberts, John D., Sullivan, Daniel, Grant, Steven, and Holkova, Beata

Published
2018
Full Text
View/download PDF

29. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Hamadani, Mehdi, Reimer, Peter, Gisselbrecht, Christian, d'Amore, Francesco, Jantunen, Esa, Ishida, Takashi, Bazarbachi, Ali, Foss, Francine, Advani, Ranjana, Fenske, Timothy S., Lazarus, Hillard M., Friedberg, Jonathan W., Aljurf, Mahmoud, Sokol, Lubomir, Tobinai, Kensei, Tse, Eric, Burns, Linda J., Chavez, Julio C., Reddy, Nishitha M., Suzuki, Ritsuro, Ahmed, Sairah, Nademanee, Auayporn, Mohty, Mohamad, Gopal, Ajay K., Fanale, Michelle A., Pro, Barbara, Moskowitz, Alison J., Sureda, Anna, Perales, Miguel Angel, Carpenter, Paul A., and Savani, Bipin N.

Published
2017
Full Text
View/download PDF

30. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Author

Trotman, Judith, Joske, David, Prince, H. Miles, Taylor, Kerry, Lewis, Ian D., Jonak, Constanze, Trautinger, Franz, Bechter, Oliver, Wolter, Pascal, Bron, Dominique, de Lima, Vladmir Claudio C., Sanches, Jose Antonio, Junior, Klasa, Richard, Bagot, Martine, Beylot-Barry, Marie, Dalle, Stephane, D'Incan, Michel, Dreno, Brigitte, Grange, Florent, Nicolay, Jan, Stadler, Rudolf, Weichenthal, Michael, Wobser, Marion, Assaf, Chalid, Loquai, Carmen, Quaglino, Pietro, Spina, Michele, Zinzani, Pier Luigi, Bosi, Alberto, Fattori, Pier Paolo, Grzanka, Aleksandra, Walewski, Jan, Lopez-Hernandez, Andres, Ortiz-Romero, Pablo L., Roca, Jose Juan Rifon, Canales, Silvana Novelli, Dummer, Reinhard, Illidge, Timothy, Johnson, Rod, Whittaker, Sean, Morris, Stephen, McKay, Pam, Scarisbrick, Julia, Duvic, Madeleine, Feldman, Tatyana, Akilov, Oleg, Geskin, Larisa, Horwitz, Steve, Kim, Youn H., Pro, Barbara, Kuzel, Timothy, Lerner, Adam, Eradat, Herbert, Sokol, Lubomir, Fisher, David C., Hughey, Sarah, Prince, H Miles, Kim, Youn H, Horwitz, Steven M, Sanches, Jose A, Ortiz-Romero, Pablo L, Akilov, Oleg E, Fisher, David, Dréno, Brigitte, Kuzel, Timothy M, Wang, Yinghui, Palanca-Wessels, Maria Corinna, Zagadailov, Erin, Trepicchio, William L, Zhang, Wenwen, Lin, Hui-Min, Liu, Yi, Huebner, Dirk, and Little, Meredith

Published
2017
Full Text
View/download PDF

39. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice

Author

Harro, Carly M., Perez-Sanz, Jairo, Costich, Tara Lee, Payne, Kyle K., Anadon, Carmen M., Chaurio, Ricardo A., Biswas, Subir, Mandal, Gunjan, Rigolizzo, Kristen E., Sprenger, Kimberly B., Mine, Jessica A., Showe, Louise C., Yu, Xiaoqing, Liu, Kebin, Rodriguez, Paulo C., Pinilla-Ibarz, Javier, Sokol, Lubomir, and Conejo-Garcia, Jose R.

Subjects
Enzyme inhibitors -- Genetic aspects -- Health aspects, Methyltransferases -- Physiological aspects -- Health aspects, T cell lymphoma -- Models -- Genetic aspects -- Development and progression, Transcription factors -- Physiological aspects -- Health aspects, Health care industry
Abstract

Cutaneous T cell lymphoma (CTCL) has a poorly understood etiology and no known cure. Using conditional knockout mice, we found that ablation of the genomic organizer special AT-rich sequence-binding protein 1 (Satb1) caused malignant transformation of mature, skin-homing, Notch-activated CD[4.sup.+] and CD[8.sup.+] T cells into progressively fatal lymphoma. Mechanistically, Satb1 restrained Stat5 phosphorylation and the expression of skin-homing chemokine receptors in mature T cells. Notably, methyltransferase-dependent epigenetic repression of SATB1 was universally found in human Sezary syndrome, but not in other peripheral T cell malignancies. H3K27 and H3K9 trimethylation occluded the SATB1 promoter in Sezary cells, while inhibition of SUV39H1/2 methyltransferases (unlike EZH2 inhibition) restored protective SATB1 expression and selectively abrogated the growth of primary Sezary cells more effectively than romidepsin. Therefore, inhibition of methyltransferases that silence SATB1 could address an unmet need for patients with mycosis fungoides/Sezary syndrome, a set of incurable diseases., Introduction Peripheral T cell lymphomas (PTCLs) represent a collection of aggressive disorders with unfavorable outcome that account for approximately 12% of lymphoid tumors worldwide (1). Cutaneous T cell lymphoma (CTCL) [...]

Published
2021
Full Text
View/download PDF

42. Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers.

Author

Saeed, Hayder, Sandoval-Sus, Jose, Castillo-Tokumori, Franco, Dong, Ning, Pullukkara, Jerrin Joy, Boisclair, Stephanie, Brahim, Amanda, Walker, Damaal, Bridgellal, Sanjay, Zhang, Ling, and Sokol, Lubomir

Subjects
ADULT T-cell leukemia, HTLV-I, CUTANEOUS T-cell lymphoma, LYMPHOMAS, T-cell lymphoma
Abstract

Introduction: Adult T-cell leukemia lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection. Despite its poor prognosis, there is no standard therapy for ATLL due to its low incidence and the disease affecting only endemic geographical clusters. Methods: A retrospective evaluation of patients with the diagnosis of ATLL at Moffitt Cancer Center and Memorial Healthcare System was done to identify patients and disease characteristics along with the progression-free survival (PFS) and overall survival (OS) for the different therapies used. Results: The 61 patients analyzed showed a median age of 58 with 82.5% of them being of African American descent. The acute variant contributed to the majority of cases (43.9%), followed by 36.8% presenting as a lymphoma variant. There was no statistical difference in the PFS (6.4 m, 3.1 m, 2.1 m; p = 0.23) or OS (14 m, 8.9 m, 18.5 m; p = 0.14) between cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), intensive chemotherapy regimens, and other modalities, respectively. However, the patients who had complete or partial remission with first-line therapy had better OS (15.9 m vs. 7.2 m; p = 0.004). Conclusions: The study highlighted the poor outcome of the current regimens and the lack of a unifying protocol for this vicious disease. The acute variants were treated with more intensive regimens, but there was no difference in the OS between the three major options of CHOP, intensified chemotherapy, and others. This underscores the need for more clinical trials to develop better outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study

Author

Kharfan‐Dabaja, Mohamed A., Al Malki, Monzr M., Deotare, Uday, Raj, Renju V., El‐Jurdi, Najla, Majhail, Navneet, Cherry, Mohamad A., Bashir, Qaiser, Darrah, Justin, Nishihori, Taiga, Sibai, Hassan, Hamadani, Mehdi, de Lima, Marcos, Gerds, Aaron T., Selby, George, Qazilbash, Muzaffar H., Forman, Stephen J., Ayala, Ernesto, Lipton, Jeffrey H., Hari, Parameswaran N., Muzzafar, Tariq, Zhang, Ling, Olteanu, Horatiu, Perkins, Janelle, Sokol, Lubomir, Kumar, Ambuj, and Ahmed, Sairah

Published
2017
Full Text
View/download PDF

48. Insights into the Impact of Hesitancy on Cancer Care and COVID-19.

Author

Visweshwar, Nathan, Rico, Juan Felipe, Ayala, Irmel, Jaglal, Michael, Laber, Damian A., Ammad-ud-din, Mohammad, Sokol, Lubomir, Sotomayor, Eduardo, and Manoharan, Arumugam

Subjects
PATIENT refusal of treatment, HEALTH services accessibility, COVID-19 vaccines, EARLY detection of cancer, CANCER patients, VACCINE hesitancy, COVID-19 pandemic, CANCER patient medical care
Abstract

Simple Summary: The impact of COVID-19 on cancer diagnosis and management during the pandemic remains uncertain. The risk of infection and travel restrictions made some cancer patients reluctant or unable to travel, hindering their access to diagnostic procedures and treatment. The pandemic also led to a shortage of health-care personnel, forcing cancer centers to limit or postpone screening procedures, such as mammography and colonoscopy, as well as elective surgeries, chemotherapy, and radiation therapy. Ophthalmic and ENT procedures, endoscopy, intubation, surgery, and chemotherapy infusions were also canceled to minimize close contact during the pandemic. This review will explore how delays in seeking medical care and reluctance to receive COVID-19 vaccinations have affected cancer patients. World Health Organization findings indicate that the COVID-19 pandemic adversely affected cancer diagnosis and management. The COVID-19 pandemic disrupted the optimal management of outpatient appointments, scheduled treatments, and hospitalizations for cancer patients because of hesitancy among patients and health-care providers. Travel restrictions and other factors likely affected medical, surgical, and radiation treatments during the COVID-19 pandemic. Cancer patients were more likely to be affected by severe illness and complications if they contracted COVID-19. A compromised immune system and comorbidities in cancer patients may have contributed to this increased risk. Hesitancy or reluctance to receive appropriate therapy or vaccination advice might have played a major role for cancer patients, resulting in health-care deficits. The purpose of this review is to evaluate the impact of COVID-19 on screening, entry into clinical trials, and hesitancy among patients and health-care professionals, limiting adjuvant and metastatic cancer treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Author

Zhang, Yumeng, Eatrides, Jennifer, Rose, Ashley, Zhang, Ling, Khimani, Farhad, Lazaryan, Aleksandr, Shah, Bijal D., Saeed, Hayder, Jain, Michael D., Liu, Hien D., Locke, Frederick L., Pinilla Ibarz, Javier, Kim, Jongphil, Kharfan-Dabaja, Mohamed A., Ayala, Ernesto, Sokol, Lubomir, and Nishihori, Taiga

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results